Capillus LLLT Device Receives FDA Clearance
Many patients use the Capillus272 as a way to maintain their hair density without transplants or as a adjunct to the transplant procedure. LLLT treatment also reduces post-operative inflammation and keeps hair stronger, healthier, and fuller over time.
Miami, FL (PRWEB) February 02, 2015
Surgeons at the Hair Transplant Institute of Miami have exciting news to share with men and women who suffer with hair loss: The Capillus272™ low level laser therapy (LLLT) device has received 510(k) clearance from the United States Food and Drug Administration (FDA), making it one of the safest and most effective LLLT products available.
It’s estimated that upwards of 55 million men and women experience hair loss in the United States alone. A majority of individuals suffer with androgenic alopecia, a specific type of hair loss that is genetically inherited. In this case, FDA clearance includes the treatment of androgenic alopecia in men and women, making the Capillus272 a convenient means of hair loss treatment that is both discreet and highly personalized.
A growing body of research and physician testimonials supports the notion that LLLT devices are effective in treating hair loss in men and women. LLLT products like the Capillus272 are also gaining the respect of patients nationwide, particularly those who elect to have a hair transplant procedure.
“Many patients use the Capillus272 as a way to maintain their hair density without transplants or as a adjunct to the transplant procedure ,” explains Dr. Bernard Nusbaum, surgeon at the Hair Transplant Institute of Miami. “LLLT treatment also reduces post-operative inflammation and keeps hair stronger, healthier, and fuller over time.”
LLLT devices like the Capillus272 are designed to reverse the signs of hair loss by rejuvenating hair follicles with laser light that is both safe and cool-to-the-touch. In a study published on the National Institute of Health in 2014, LLLT devices demonstrated the ability to yield up to 20 new hairs per squared centimeter of scalp.
This double-blind, randomized, sham device-controlled study was the first to prove LLLT effective in treating symptoms of hair loss. The Capillus272 emits much more energy compared to those devices tested in 2014, featuring more than 20 times the number of medical laser diodes in a flexible dome that comfortably covers the patient’s entire scalp.
In addition to prescribing advanced LLLT devices for hair loss, the Hair Transplant Institute of Miami offers unparalleled expertise and experience in hair loss diagnosis, treatment, and care. To learn more about the Institute’s newest technologies and treatment options, including the revolutionary new ARTAS® System for follicular unit extraction (FUE), readers are invited to log-on to http://www.miamihair.com or call toll free 1-877-443-9070.